Secukinumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Secukinumab
- Secukinumab: From Autoimmune Inflammatory Disease to Primary Release Disorder of Platelets
Secukinumab: From Autoimmune Inflammatory Disease to Primary Release Disorder of Platelets
One-Sentence Summary
Secukinumab is an IL-17A monoclonal antibody originally used for autoimmune inflammatory diseases such as psoriasis and ankylosing spondylitis. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but currently no clinical trials and no supporting literature exist for this specific pairing — the prediction is model-driven only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune inflammatory disease (e.g., psoriasis, ankylosing spondylitis) — noted in rationale text only; no formal indication record in this evidence pack |
| Predicted New Indication | Primary Release Disorder of Platelets |
| TxGNN Prediction Score | 98.16% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data for Secukinumab is flagged as a data gap in this evidence pack (DG002, High severity). Based on the limited context available, Secukinumab is described as an IL-17A monoclonal antibody used to treat autoimmune inflammatory conditions such as psoriasis and ankylosing spondylitis, working by blocking IL-17A-driven inflammatory signaling.
Primary release disorder of platelets, however, is a congenital platelet function defect — a structural/storage-pool abnormality, not an inflammatory or autoimmune condition. The evidence pack’s own rationale explicitly states there is no known direct mechanistic link between IL-17A signaling and this disorder, and that the original MOA data being a gap prevents proper cross-validation.
In short, this is a high-confidence TxGNN embedding-similarity score without any mechanistic, clinical, or literature corroboration. The prediction should be treated as a research hypothesis only, not a repurposing candidate ready for further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Secukinumab is currently not marketed in the EU per this evidence pack (0 authorizations on record, no license entries available to summarize).
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack — TFDA label warnings/contraindications are flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on a TxGNN embedding score with no clinical trials, no literature support, and an explicitly weak/absent mechanistic rationale (congenital platelet defect vs. IL-17A-driven inflammatory pathway). The drug is also not currently marketed in the EU, and core safety data (warnings, contraindications, DDI) are unavailable.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (currently a Blocking data gap, DG001)
- Verified mechanism-of-action data for Secukinumab (currently a High-severity data gap, DG002)
- Preclinical or mechanistic studies exploring any IL-17A involvement in platelet release disorders
- At minimum, case reports or observational data before considering any further evaluation stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.